Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Click here to view

Presentation

Presentation: Directed Evolution of Bxb1 for the Development of Modular Integrases (MINTS)

Download PDF